Hot Point Problems in Clinical Diagnosis, Treatment and Management of Pulmonary Hypertension: Comparison and Interpretation of 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension and Chinese Guidelines for the Diagnosis and Treatment of Pulmonary Artery Hypertension (2021 Edition)

Abstract

The clinical and translational research of pulmonary hypertension (PH) has been continuously deepened, which has promoted the updating of PH related guidelines. On August 26, 2022, the European Society of Cardiology (ESC) and the Respiratory Society (ERS) jointly released the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension (hereinafter referred to as the "2022 ESC/ERS Guidelines") . In January 2021, Chinese Thoracic Society and Chinese Association of Chest Physicians jointly released the Chinese Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension (2021 Edition) (hereinafter referred to as the "Chinese Guidelines") , in which a lot of recommendations were put forward in line with China's national conditions combining with the research at home and abroad at that time. This paper will focus on the interpretation of the update points of the ESC/ERS Guidelines in combination with the relevant contents of the Chinese Guidelines.

Keywords

• pulmonary arterial hypertension|diagnosis|therapy|guidebook|interpret|disease management